Alkermes (ALKS) EBITDA Margin (2010 - 2026)
Alkermes (ALKS) posted quarterly EBITDA Margin of 3.7% for Q2 2026, down 2010.0% year-over-year from 0.19% in Q2 2025, and up 130.11% quarter-over-quarter from 12.29% in Q1 2026.
Alkermes (ALKS) EBITDA Margin (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported EBITDA Margin for 17 consecutive years, with 3.7% the latest figure, recorded in Q2 2026.
- In Q2 2026, EBITDA Margin fell 2010.0% year-over-year to 3.7%; the TTM figure through Jun 2026 stood at 7.03% (down 1783.0% YoY), while the FY2025 annual figure was 17.21%, down 980.0% from the prior year.
- EBITDA Margin improved to 3.7% in Q2 2026 per ALKS's latest filing, from 12.29% in the prior quarter.
- Across five years, EBITDA Margin topped out at 45.56% in Q2 2023 and bottomed at 1895.03% in Q3 2022.
- Historically, EBITDA Margin has averaged 150.05% across 5 years, with a median of 14.79% in 2023.
- Annual changes were most pronounced in 2022 — EBITDA Margin slumped 188835 bps — and 2023, when it jumped 191845 bps.
- Alkermes' EBITDA Margin stood at 37.94% in 2022, then tumbled by 62 bps to 14.47% in 2023, then jumped by 161 bps to 37.84% in 2024, then tumbled by 60 bps to 15.11% in 2025, then tumbled by 76 bps to 3.7% in 2026.
- Business Quant data shows ALKS's EBITDA Margin at 3.7% in Q2 2026, 12.29% in Q1 2026, and 15.11% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.19 Bn | 19.53 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.68 Bn | 17.79 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.96 Bn | - | - |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 3.70% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.70% |
| Mar 31, 2026 | -12.29% |
| Dec 31, 2025 | 15.11% |
| Sep 30, 2025 | 22.60% |
| Jun 30, 2025 | 23.80% |
| Mar 31, 2025 | 4.50% |
| Dec 31, 2024 | 37.84% |
| Sep 30, 2024 | 27.70% |
| Jun 30, 2024 | 27.53% |
| Mar 31, 2024 | 12.36% |
| Dec 31, 2023 | 14.47% |
| Sep 30, 2023 | 23.41% |
| Jun 30, 2023 | 45.56% |
| Mar 31, 2023 | -3.82% |
| Dec 31, 2022 | 37.94% |
| Sep 30, 2022 | -1,895.03% |
| Jun 30, 2022 | -1,076.78% |
| Mar 31, 2022 | -9.54% |
| Dec 31, 2021 | 39.89% |
| Sep 30, 2021 | -6.68% |